Anti-miR-33 treatment, especially anti-miR-33b treatment, improved the lipid profile in the serum and liver, which explains the amelioration of the GAN diet–induced NASH phenotype in miR-33b KI mice via the up-regulation of ABCA1 and other lipid regulatory genes. Here, ABCA1 is linked to metabolic dysfunction-associated steatohepatitis.